Selected Non-Hodgkin's Lymphoma abstracts from the American Society of Hematology (ASH) 2010 convention in Orlando Florida

http://ash.confex.com/ash/2010/webprogram/start.html


List compiled by Greg Dafoe

See the new 2013 abstracts

Home
NHL Cyberfamily Home

Table of contents

  1. Clinical Care - Recurrence, Secondary Neoplasia and Late Complications after Transplantation: Poster I
  2. Clinical Care - Transplantation Regimen Toxicities and Engraftment: Poster I
  3. Clinical Results - Autologous Transplantation
  4. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Poster I
  5. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster I
  6. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Poster I
  7. Clinical Care - Transplantation Regimen Toxicities and Engraftment: Preparative Regimens
  8. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Aggressive Non-Hodgkin Lymphoma Therapy
  9. Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Novel Targeted Therapies
  10. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Microenvironment
  11. Clinical Results - Alternative Donor Transplantation: Poster I
  12. Clinical Results - Autologous Transplantation: Poster I
  13. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Poster II
  14. Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster I
  15. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II
  16. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Immunotherapeutics and Small Molecule Inhibitors
  17. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Clinical Correlations
  18. Clinical Results - Alternative Donor Transplantation II
  19. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Hodgkin and Primary Mediastinal Large B-cell Lymphoma
  20. Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Novel Immune-Mediated Approaches
  21. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Immunotherapy for Indolent Lymphoma
  22. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Biologic Mechanisms of Lymphomagenesis
  23. Clinical Results - Allogeneic Matched Related Donor Transplantation
  24. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Aggressive Lymphoma and Radioimmunotherapy
  25. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Gene Profiling/Signaling
  26. Clinical Results - Autologous Transplantation: Lymphoma
  27. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Therapy of Hodgkin Lymphoma and Indolent Non-Hodgkin Lymphoma
  28. Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Preclinical Advances in Mantle Cell Lymphoma
  29. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Advanced Technology in Non-Hodgkin Lymphoma Genetics
  30. Clinical Results - Allogeneic Matched Related Donor Transplantation: Poster I
  31. Clinical Results - Alternative Donor Transplantation: Poster II
  32. Clinical Results - Autologous Transplantation: Poster III
  33. Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster II
  34. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III
  35. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Poster III
  36. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Chemotherapy and PET in Non-Hodgkin Lymphoma
  37. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Novel approaches for T Cell and Mantle Cell Lymphoma
  38. Non-Hodgkin Lymphoma - Biology, excluding Therapy: New Biomarkers in Diffuse Large B-cell Lymphoma

Clinical Care - Recurrence, Secondary Neoplasia and Late Complications after Transplantation: Poster I

1287 Long Term Study of the Impact of Quantitative Molecular Monitoring of Bcr-Abl Transcripts on the Risk of Relapse of CML After Allogeneic HSCT

1288 Treatment of Recurrent or Persistent AML/MDS After Allogeneic Hematopoietic Cell Transplantation with Azacitidine

1289 The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients 

1290 High-Throughput VDJ Sequencing Is Superior to Quantitative PCR and Flow Cytometry for the Quantification of Minimal Residual Disease In Chronic Lymphocytic Leukemia After Hematopoietic Cell Transplantation

1291 Outcome of Relapse After Allogeneic Transplantation for Childhood Acute Lymphoblastic Leukemia In Complete Remission. A Study of the Pediatric Diseases and Acute Leukemia Working Parties of the EBMT Group

1292Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors

1293Azacytidine (AZA) In Relapsed MDS and AML After Allogeneic Stem Cell Transplantation (allo-HSCT): Results of the French ATU Program

1294 Azacitidine (Vidaza®, Aza) and Donor Lymphocyte Infusions (DLI) In Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Interim-Analysis From the AZARELA-Trial (NCT-00795548) 

1295  Outocomes of Second Unrelated Cord Blood Transplant for Relapse After First Allogeneic Transplant In Adult Patients with Progressive Acute Myeloid Leukimia/Myelodysplastic Syndrome

1296 “Secondary MGUS” After High-Dose Melphalan and Autologous Hematopoietic Progenitor Cell Transplantation In Multiple Myeloma:  A Matter of Undetermined Significance

1297 Chimerism Kinetics of Unfractionated Bone Marrow In the First Year After Allogeneic Hematopoietic Cell Transplantation Is Predictive of Relapse In Patients with AML and MDS

1298 The Cutoff Leukemic Cell Burden to Influence Outcomes of Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia In Hematological Complete Remission

1299 Results of a Prospective Clinical Trial of Pre-DLI Lymphoreduction Using Oral Fludarabine In Patients with Mixed Chimerism Post Allogeneic Transplant

1300 Donor Lymphocyte Infusions and Second Transplantation as Salvage Treatment for Relapsed Myelofibrosis After Reduced-Intensity allografting 

1301 Patterns of Serum Free Light Chain (FLC) Recovery After Reduced Intensity Conditioning (RIC) Allogeneic Transplant for Multiple Myeloma (MM) Predict Long Term Outcomes

1302 The Genotype of the Donor for the Polymorphism A7488G of the IL-17 Gene Influences relapse and survival After HLA-Identical Related Stem Cell Transplantation

1303 Multiple Mutations of CEBPA Contribute to Leukemogenesis: The Donor Origin of Leukemia Relapse After Allogeneic Hematopoietic Cell Transplantation

1304 Alemtuzumab-Based RIC HSCT with Pre-Emptive DLI as An Effective Strategy to Achieve Long-Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML)

1305 Thyroid Function Abnormalities In Adults Following Haematopoetic Stem Cell Transplant (HSCT)

1306 Donor-Derived Myelodysplastic Syndrome and Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Incidence, Natural History and Treatment Response

1307 The Ratio of Pre-Transplant Serum Ferritin to the Units of Blood Transfused and Not Serum Hepcidin Strongly Correlates with Outcome After Allogeneic Hematopoietic Cell Transplantation In Patients with AML and MDS

Clinical Care - Transplantation Regimen Toxicities and Engraftment: Poster I

1308 Safety and Feasibility of Posaconazole as Oral Antifungal Prophylaxis In Pediatric Patients Under 12 Years of Age Following Allogeneic Stem Cell Transplantation

1309 Brain Natriuretic Peptide (BNP) Elevations In Allogeneic Stem Cell Transplant (ASCT) Recipients at the Time of WBC Engraftment. Correlation with Engraftment Syndrome and Cardiac Dysfunction

1310 25-OH Vitamin D Deficiency Following Pediatric Hematopoietic Stem Cell Transplant

1311 Aprepitant (Emend®) Significantly Increases Sirolimus Levels In Patients Undergoing Allogeneic Hematopoietic Stem Cell transplantation 

1312 Primed-GCSF BMT Following Reduced Intensity Conditioning Regimen (RIC) for Patients (pts) with Poor-Prognosis, Heavily Pre-Treated, Hodgkin’s Disease (HD)

1313 Primed-GCSF BMT After Reduced Intensity Conditioning (RIC) In Association with Rituximab for Patients (pts) with Refractory CD20+ Aggressive Lymphomas.

1314 Does Bisphosphonate-Induced Osteonecrosis of the Jaw (BONJ) Preclude Intensive Chemotherapy? Oral and Infectious Toxicities Associated with Autotransplantation In Patients with BONJ

1315 Prognostic Factors on Survival After Hematopoietic Stem Cell Transplantation for Adult Over 40 Years In Aplastic Anemia

1316 Use of RIC-Allosct In Patients Younger Than 45 Years Old Affected by MDS and Leukemia: A Monocenter Retrospective Analysis

1317 Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy In Adults with Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation

1318 Cyclophosphamide and Prednisone Induction Effectively Decreased the Incidence of Engraftment Syndrome In Patients with POEMS Syndrome Who Undergo Stem Cell Transplantation

1319 Pre-Transplant Rituximab Is Associated with Reduced Rate of Acute GvHD After RIC-Allosct In Lymphoma Patients: Results From A Retrospective Monocenter Analysis 

1320 Phase 2 Study of Allogeneic Stem Cell Transplantation (ASCT) From Matched Related Donor (MRD) In Patients Older Than 55 Years After Reduced Intensity Conditioning (RIC) Associating Fludarabine, Intravenous Busulfan and Rabbit Thymoglobulin

1321 T Cell Chimerism After T Cell Depleted Allogeneic Stem Cell Transplantation Is Influenced  by Immunological Factors Including the Conditioning Regimen, CMV Serostatus and GvHD and Does Significantly Bias Overall Chimerism Status

1322 Poor FEV1 or DLco on Pre-Transplant PFT Does Not Compromise Outcomes In Patients Undergoing a Reduced-Intensity Allogeneic Progenitor Cell Transplant

1323 Syngeneic Donor Hematopoietic Stem Cell Transplantation Is Associated with High Rates of Engraftment Syndrome

1324 Intravenous Busulphan in Combination with ETOPOSIDE and MELPHALAN Used as Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Lymphomas: Evaluation of Toxicity and Efficacy

1325 Low Day 30 Total Donor Chimerism After Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Poorer Overall Survival In Myeloid but Not Lymphoid Disorders

1326 The HCT-Specific Comorbidity Index Fails to Predict Survival After Allogeneic HCT In High Risk AML Patients - A Single Center Experience

1327 Treosulfan, Etoposide and Cyclophosphamide as Non TBI-Conditioning Regimen Followed by Allogeneic SCT for Acute Lymphoblastic Leukemia

1328 Dynamics of Chimerism In Regulatory T Lymphocytes (Treg; CD4+/CD25+) After Allogeneic Stem Cell Transplantation

1329 Successful Control of Preexistent Active Infection by Granulocyte Transfusions During Conditioning Induced Cytopenia In Patients with Chronic Granulomatous Disease Undergoing Hematopoietic Stem Cell Transplant

1330 Veno-Occlusive Disease After Haematopoietic Stem Cell Transplantation for β Thalassaemia Major Is Predicted by the Severity of Hepatic Fibrosis and Ameliorated by Defibrotide

1331 Serum Ferritin and Cardiac/Liver Magnetic Resonance Imaging In Evaluating Iron Overload for Patients with Bone Marrow Failure Conditions Undergoing Non-Myeloablative HSCT

1332 Chimerism Analysis Is Predictive of Relapse-Free Survival After Allogeneic Transplantation for MDS

1333 Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

1334 A Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation  for Patients with Refractory leukemia 

1335 Combined Use of Multi-Day Doses of Palonosetron and Aprepitant with Low Dose Dexamethasone In Prevention of Nausea and Emesis Among Patients with Multiple Myeloma and Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplant (ASCT): A Pilot Study 

1336 Long-Term Results of a Fast Transplant Versus a Classical Conditioning Strategy for Allogeneic Stem Cell Transplantation of High Risk Acute Myeloid Leukemia (AML) Patients 

1337 The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) and Survival After Extracorporeal Photopheresis, Pentostatin, and Reduced Dose Total Body Irradiation (TUFTs) Conditioning Prior to Allogeneic Stem Cell Transplantation (SCT)

1338 T-Cell Depletion Is An Alternative Approach for Patients >/= 55 Years Undergoing Allogeneic Stem Cell Transplantation  as Curative Therapy for Hematologic Diseases

1339 CD34+ Cell Dose Is the Major Cell Dose Determinant of Myeloid Engraftment After Single Umbilical Cord Blood Transplantation (sUCBT) for Adult Patients with High-Risk Hematologic Malignancies

1340 Higher Non-Relapse Mortality with BuCyVP Compared to BuCy In Allogeneic Hematopoietic Stem Cell Transplant

Clinical Results - Autologous Transplantation

1341 The Role of High Dose Chemotherapy and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma Refractory to Initial Induction Therapy

1342 Prognostic Index for Predicting Overall Survival and Event-Free Survival In Total Therapy 3 Patients

1343 Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study

1344 Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone In Patients with AL (Primary) Amyloidosis: Long Term Follow-up of the French Multicentric Randomized Trial

1345 Multiple Myeloma Patients Who Are Chemosensitive and Present with Plasma Cells Lacking  Phosphorylated Retinoblastoma and/or  Cyclin A  Expression Benefit From High Dose Therapy and Autologous Stem Cell Transplantation More

1346 Population-Based Study of the Outcomes of Primary Central Nervous System Lymphoma (PCNSL) In the Era of Autologous Stem Cell Transplantation (ASCT)

1347 Response to Induction Chemotherapy with Novel Agents Does Not Predict Outcomes of Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

1348 The Introduction of Novel Agents Improves Outcomes of Young Patients with Myeloma (MM) Treated with Autologous Stem Cell Transplant (ASCT)

1349 Effect of Pharmacokinetic Variability on the Toxicity and Efficacy of High-Dose Melphalan for Multiple Myeloma

1350 High Dose Melphalan with Autologous Stem Cell Transplantation Overcomes Poor Prognosis of Primary Amyloidosis

1351 Impact of Response to Thalidomide, Lenalidomide or Bortezomib Containing Induction Chemotherapy on Outcomes of Multiple Myeloma Patients Undergoing Autologous Transplantation – A Multicenter Analysis

1352 Autotransplants for Multiple Myeloma (MM) – An Update of the Arkansas Experience Since 1989 In Almost 4000 Patients with Special Emphasis on Third and Further Transplants

1353 Outcomes Following Salvage Autologous Stem Cell Transplant for Multiple Myeloma

1354 Analysis of Serial Body Height Measurements In Total Therapy 2 (TT2, Control v Thalidomide Arm) and Total Therapy 3 (A: VTD Maintenance; B: VRD Maintenance) as a Guide to Overall Bone Health In Multiple Myeloma (MM)

1355 High Dose Intravenous Busulfan (BU) and Melphalan (MEL ) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM)

1356 Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components

1357 The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions

1358 High-Dose Therapy (HDT) with Hematopoietic Stem Cell Transplantation (HSCT) Is Effective Therapy for Patients with Non-Hodgkin Lymphoma (NHL) and Central Nervous System (CNS) Involvement

1359 Pharmocokinetic (PK)-Directed High Dose Intravenous Busulfan, Cyclophosphamide and Etoposide Produces Predictable Drug Exposure and Durable Long Term Survival In Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Poster I

1748 Herpesviridae Viral Infections Following Rituximab Combined Chemotherapy In Patients with Diffuse Large B Cell Lymphoma

1749 Bortezomib May Be Safely Combined with Y-90 Ibritumomab Tiuxetan In Patients with Relapsed/Refractory Follicular or Transformed Non-Hodgkin Lymphoma:  A Phase I Trial of Combined Induction Therapy and Bortezomib Consolidation

1750 Phase II Study of Intrathecal Long Acting Liposomal Cytarabine (Depocyte®) In the Prophylaxis of Lymphomatous Meningitis In HIV-Related Non-Hodgkin's Lymphoma

1751 Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment

1752 Post-Transplant Lymphoproliferative Disease In Liver Transplant Recipients: A Single Institution Experience

1753 Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens

1754 BACOPP-D - An Etoposide-Free Dose-Escalated Polychemotherapy Regimen In Advanced Hodgkin`s Lymphoma

1755 Use of Cytarabine for Mantle Cell Lymphoma Treatment: 10 Years of Experience of a French Haematology Department

1756 Incidence, Method and Covariates of Central Nervous System (CNS) Prophylaxis for Diffuse Large B-Cell Lymphoma In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

1757 Fludarabine Plus Cyclophosphamide and Rituximab In Waldenström's Macroglobulinemia: Results In 55 Patients

1758 High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial

1759 An Effective Salvage Treatment Using Rituximab, Ifosfamide, Etoposide, Cytarabine, and Dexamethasone (R-IVAD) for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

1760 RCHOP Therapy Overcome Gastric Diffuse Large B Cell Lymphoma without Surgery

1761 Therapeutic and Mobilizing Activity of a Vinorelbine, Ifosfamide and Cytarabine Regimen (VIHA) as Salvage Regimen In Resistant/Relapse Non Hodgkin Lymphoma  (NHL)

1762 Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF)

1763 Mocetinostat (MGCD0103), An Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, Produces Clinical Responses In Relapsed/Refractory Hodgkin Lymphoma (HL): Update From a Phase II Clinical Study

1764 High Incidence of Cardiovascular Complications After CHOP-Like Chemotherapy In Lymphoma Patients From Poland – Retrospective Analysis of Polish Lymphoma Research Group (PLRG)

1765 Concurrent Chemo-Radiotherapy Followed by VIDL (Etoposide, Ifosfamide, Dexamethasone, L-asparaginase) Chemotherapy In Stage I/II Extranodal NK/T-Cell Lymphoma of Nasal Cavity/Nasopharynx

1766 Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14)

1767 Aplidin® (Plitidepsin) Activity In Peripheral T-Cell Lymphoma (PTCL): Final Results

1768 Does An Anthracycline Make a Difference for Follicular Lymphoma (FL) Grade 3? Patterns of Care and Treatment Outcomes of Grade 3 FL From the National LymphoCare Study (NLCS)

1769 Bortezomib (VELCADE), Rituximab, Cyclophosphamide, Dexamethasone (VRCD) Combination Therapy In Front-Line Low-Grade Non-Hodgkin Lymphoma (LG-NHL) Is Active In Elderly Patient Population

1770 PRIMARY EXTRANODAL MARGINAL ZONE LYMPHOMA of the LUNG (BALT-LYMPHOMA): Results of a Retrospective Analysis on Behalf of IELSG

1771 Outcome of Elderly Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Prospectively Identified by Comprehensive Geriatric Assessment (CGA). Results From a Study of the Intergruppo Italiano Linfomi (IIL)

1772 PET-CT Adapted Therapy After 3 Cycles of ABVD for All Stages of Hodgkin Lymphoma. Interim Analysis in 173 Patients

1773 Blastoid Variant of Mantle Cell Lymphoma (MCL) Is Associated with P53 Abnormalities and Have a Shorter Progression-Free Survival (PFS) and Overall Survival (OS) Despite Upfront Chemo-Immunotherapy Followed by High Dose Chemotherapy and Autologous Stem Cell Support (HDC-ASCS)

1774 Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies

1775 A Phase I Dose-Escalation Trial of Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

1776 Whole Brain Radiotherapy and Ara-C In Consolidation Post High-Dose Methotrexate Is Important In Establishing Durable Disease Control In the Treatment of Primary CNS Lymphoma: A Single Centre Observational Study

1777 Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

1778 Toxicity and Response Among Octogenarians and Nonagenarians with Diffuse Large B Cell Lymphoma Treated with Rituximab-CHOP Therapy

1779 Single 4.5mg Dose of Rasburicase for Tumor Lysis Syndrome In Adults

1780 Clinical Relevance of the Dose of Cytarabine In the Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Chemotherapy Combination

1781 Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab

1782 R-HCVAD/R-MTX-Arac (R-HCVAD) Overcomes Risk Features Associated with Inferior Outcomes In the Treatment of Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

1783 Phase I Study of Novel Prodrug Dual PI3K/mTOR Inhibitor SF1126 In B-Cell Malignancies

1784 Retrospective Analysis of 206 Mantle Cell Lymphoma Patients at Diagnosis: Mantle Cell International Prognostic Index (MIPI) Is a Good Predictor of Death Event In Patients Treated Either with Rituximab-Chemotherapy or Rituximab-High-Dose-Chemotherapy

1785 Fludarabine Plus I-131 Tositumomab as Initial Treatment for Follicular Lymphoma: Half of Patients In Remission at Over 10 Years Median Followup

1786 Intensified 1st Cycle Rituximab (R) Plus 8th Cycles of R-CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) Chemotherapy In Patients with Advanced or Bulky CD20+ Diffuse Large B-Cell Lymphoma (DLBCL); Open-Labelled, Multicenter Phase II CISL Study-Interim Analysis

Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster I

1787 Interim Results of a Phase 1 Trial of An Oral Histone Deacetylase Inhibitor Belinostat In Patients with Lymphoid Malignancies

1788 Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy

1789 Preclinical and Clinical Binding Properties, Internalization Kinetics, and Clinicopathological Activity of Brentuximab Vedotin (SGN-35): A Novel Antibody Drug Conjugate for Anaplastic Large Cell Lymphoma and Classical Hodgkin Lymphoma

1790 Matched Pair Analysis Comparing the Outcomes of Primary Breast and Nodal Diffuse Large B Cell Lymphoma In Patients Treated with R-Chop; Consortium for Improving Survival of Lymphoma (CISL) Study

1791 The Efficacy of Bortezomib-CHOP In Patients with Advanced Stage T or NK/T Cell Lymphomas: The Results of Multicenter Phase II Study

1792 Rapid Prospective Identification of Non-Germinal Center B Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Targeted Trials: Early Results From PYRAMID, A Phase 2 Randomized Study of R-CHOP ± Bortezomib In Newly Diagnosed Non-GCB DLBCL

1793 Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

1794 Efficacy and Safety of Thalidomide In Mantle Cell Lymphoma: Results of the French ATU Program

1795 A Phase II Trial of Ofatumumab In Subjects with Waldenstrom’s Macroglobulinemia

1796 Phase I Study of Forodesine (BCX1777), An Oral PNP Inhibitor In Patients with Relapsed or Refractory T/NK Malignancies

1797 Pooled Analysis of Aids-Malignancy Consortium (AMC) Trials Evaluating Rituximab Plus Either CHOP or Infusional EPOCH Chemotherapy In HIV-Associated Non-Hodgkin’s Lymphoma

1798 Rituximab maintenance for the Treatment of patients with Follicular Lymphoma: Systematic Review and Meta-Analysis of Randomized Trials - 2010 Update

1799 Prognostic Significance of Interim 18f-FDG PET/CT for the Treatment of Diffuse Large B-Cell Lymphoma In the Post-Rituximab Era

1800 Clinical Significance of Immunohistochemical Markers of Diffuse Large B-Cell Lymphoma In the Rituximab Era

1801 Phase II Study of Velcade® Plus Mabthera®  In Relapsed Follicular Lymphomas

1802 Rituximab Maintenance Treatment for a Maximum of 5 Years In Follicular Lymphoma: Safety Analysis of the Randomized Phase III Trial SAKK 35/03

1803 Front-Line Therapy with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) Followed by 2 Years of Rituximab Maintenance for Follicular Lymphoma (FL) Is Associated with Excellent Outcomes and Improved Progression-Free Survival (PFS) In Comparison to No Maintenance

1804 A Novel Cancer Vaccine Strategy In Previously Untreated Patients with Stage III/IV Follicular Lymphoma Generates Tumor-Reactive T Cells and Clinical Response

1805 Low Absolute Lymphocyte Count and Addition of Rituximab Confer High Risk for Interstitial Pneumonia In Patients with Diffuse Large B Cell Lymphoma

Non-Hodgkin Lymphoma - Biology, excluding Therapy: Poster I

1993 Pretreatment Serum Level of 15-KDa Granulysin Might Predict Recurrence and Survival of Diffuse Large B Cell Lymphoma Patients Treated by R-CHOP Regimen. 

1994 Increased Risk of Second Malignancies In Young Patients with Mycosis Fungoides Diagnosed Before 30 Years of Age: A Population-Based Study

1995 Clinical and Molecular Significance of Tumor Necrosis In Newly Diagnosed Patients with Hodgkin's Lymphoma and Diffuse Large B Cell Lymphoma

1996 Cytogenetic Aberrations In Splenic Marginal Zone Lymphoma (SMZL): A Study On 134 Cases

1997 Targeted Knock-Down of CD44 Expression In DLBCL Cells with Retrovirus-Mediated shRNA Interference

1998 NF-κB Is Constitutively Activated in EBV-Infected T or NK Cells and Can Be a Molecular Target for EBV-Positive T/NK-Cell Lymphoproliferative Disease Treatment

1999 A Newly Identified Translocation t(X;14)(p11;q32) In MALT Lymphoma Involving IGHS and GPR34  Reveals A Novel Role for GPR34 In Cell Growth and Tumor Development 

2000 Gain of CD20 Target Cell Surface Receptor Expression During Serum-Free Ex Vivo Culture of CD19+CD5+ B-Cells In a Sub-Population of Early Stage (Rai 0/1) Chronic Lymphocytic Leukemia Patients

2001 Single Nucleotide Polymorphism Array (SNP-A) Genomic Profiling of Mantle Cell Lymphoma (MCL) Against a Large Control Database Reveals Recurring Copy Number Alterations (CNAs) and Copy Neutral Loss of Heterozygosity (CN-LOH)

2002 CD5-Negative Monoclonal B-Cell Lymphocytosis (MBL) Is Detectable In 9% of Adults Aged Over 40 but Phenotypes Associated with Clinically Common Non-Hodgkin Lymphomas Are Infrequent (<2%)

2003 Kinetics of Regulatory T-Cells Are Highly Influenced by Treatment In Patients with Gastric MALT Lymphoma

2004 Biological and Therapeutic Significance of Thioredoxin-1 (Trx-1) In Diffuse Large B-Cell Lymphomas

2005 Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP

2006 Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment

2007 Identification of Potential Prognostic Biomarkers in Mantle Cell Lymphoma by Array-Based Quantitative Nuclease Protection Assay

2008 A Germinal Center- Derived B Cell Lymphoma Model

2009 Cytogenetic Aberrations In Lymphoplasmacytic Lymphoma (LPL): A Study On 166 Cases

2010 Microarray Analysis of the Peripheral Monocytes From Waldenstrom’s Macroglobulinemia Patients Reveals a Distinct Gene Expression Profile

Clinical Care - Transplantation Regimen Toxicities and Engraftment: Preparative Regimens

31 A Novel High Dose Chemotherapy Strategy with Bendamustine In Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: a Phase I-II Study on 44 Patients

32 Comparative Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy (RIT) Based Conditioning Versus Total Body Irradiation (TBI) for High-Risk Diffuse Large Cell Lymphoma (DLCL): Toxicity and Efficacy

33 Y-90-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for High-Risk B-Cell Lymphoma

34 Prospective Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition to Anti-Thymocyte Globulin for the Conditioning Therapy In Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome

35 Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan x 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML

36 Dose Escalation of Clofarabine In Combination with Cytarabine and Total Body Irradiation (TBI) Followed by Allogeneic Stem Cell Transplantation (AlloSCT) In Children, Adolescents and Young Adults (CAYA) with Poor-Risk Acute Leukemia

Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Aggressive Non-Hodgkin Lymphoma Therapy

109 A Prospective Randomized Study Comparing Dose Intensive Immunochemotherapy with R-ACVBP vs Standard R-CHOP In Younger Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Groupe d’Etude Des Lymphomes De l’Adulte (GELA) Study LNH03-2B

110 Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)

111 Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (<61 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL) with a CHOP-like Regimen with or without the Anti-CD20 Antibody Rituximab – 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group

112 CNS Disease In Younger Patients (<=60 years) with Aggressive Lymphoma Treated In Trials of the German High Grade Non Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT)

113 Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)

114 Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy

Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Novel Targeted Therapies

115 HDAC Class I Inhibition Acetylates a Non-Histone Protein STAT3 by Modulating p300-STAT3-HDAC1 Interaction In Activated B- Cell Like (ABC) Diffuse Large B Cell Lymphoma

116 Potentiation of Bortezomib-Induced Killing of Lymphoma Cells by Inhibition of Autophagy and Prevention of I-κBα Degradation

117 Metabolic Targeted Therapy for Aggressive B-Cell Lymphomas:  Evaluating Glucose Metabolism and the Potential of 187rhenium- Ethylenedicysteine –N-AcetylGlucosamine (187Re-ECG) for Therapy

118 The Novel Kinesin Spindle Protein Inhibitor SB-743921 Exhibits Marked Activity In In Vivo and In Vitro In Models of Aggressive Diffuse Large B-Cell Lymphoma

119 Targeting Translation Bypasses Pim Kinase Activity, a Common and Adverse Prognostic Marker In Lymphoma

120 Targeting Sp1 Transactivation In Waldenstrom’s Macroglobulinemia: a Novel Therapeutic Option

Non-Hodgkin Lymphoma - Biology, excluding Therapy: Microenvironment

139 Non-Stereotypic Follicular Lymphoma B-Cell Receptors Recognize Vimentin as a Shared Autoantigen

140 Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma

141 Differential Gene Expression Profile Identifies Defects and Abnormalities In Infiltrating T Cells In Patients with Follicular Lymphoma at Diagnosis

142 Eph-B2/Ephrin-B2 Interaction Plays a Major Role In the Adhesion and Survival of WM Cells In the Context of the Bone Marrow Microenvironment

143 A Novel IL-12-TIM-3 Pathway Induces T Cell Exhaustion and Predicts Reduced Survival In Patients with Follicular B-Cell Non-Hodgkin Lymphoma

144 NF-κB Signaling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome

Clinical Results - Alternative Donor Transplantation: Poster I

2347 Imatinib Mesylate Versus Allogeneic HSCT for Patients with Chronic Myelogenous Leukemia In Accelerated Phase: A Single Center Experience In China After a 9-Year Follow-up

2348 Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia After Prior Treatment with Nilotinib or Dasatinib

2349 Reduced-Intensity Unrelated Cord Blood Transplantation (RICBT) for Elderly Patients with Hematological Malignancies

2350 Unmanipulated Bone Marrow Transplantation From Haploidentical Related Donor for Patients with High-Risk Hematological Malignancies

2351 A Novel Reduced Intensity Conditioning Can Induce a High Incidence of Sustained Donor Engraftment After Double Unit Cord Blood Transplantation (CBT) without Anti-Thymocyte Globulin

2352 In Vitro Assessment of Tolerance and Rejection Occurring After Co-Transplantation of Allogeneic Umbilical Cord Blood and Haploidentical CD34+ Cells as Treatment for Severe Aplastic Anemia

2353 Phase II Prospective Multicenter Study of Treosulfan Based Reduced Intensity Conditioning In Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies From 10/10 HLA Identical Unrelated Donor

2354 A Phase I-II Dose Escalation Trial of Clofarabine Plus Melphalan and Thiotepa Followed by Unmodified Allogeneic Stem Cell Transplant (SCT) for the Treatment of High Risk or Advanced Acute Leukemia

2355 Long-Term Outcomes of TBI-Based Myeloablative SCT In 292 Consecutive Adults with Ph-Negative ALL: Similar Outcomes for Transplantation Using Related Donor, Well-Matched Unrelated Donor, or Partially Matched Unrelated Donor Sources

2356 Older Patients with AML Undergoing Matched Related Allogeneic Transplantation Have Significantly Older Donors but Equivalent Survival as Patients Receiving Unrelated Donor Transplants

2357 Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial

2358 A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation

2359 Disease Status Is the Major Prognosis Factor for Allogenic Transplantation Outcome for Hodgkin Lymphoma: a Retrospective Study From the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)

2360 Outcomes In Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T-Cell Lymphoma: A Single Center's 12-Year Experience

2361 Reduced Intensity Allogeneic Tranplants Are Well Tolerated In Patients Over the Age of 60: Identification of Factors Predicting Overall Survival

2362 HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

2363 Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Pediatric Patients with Treatment Related Myelodysplastic Syndrome or Acute Myelogenous Leukemia (tMDS/AML)  

2364 Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

2365 Sequential Autologous Followed by Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors Improves Outcomes of Patients (pts) with Bulky Lymphoma or Chronic Lymphocytic Leukemia (CLL)

2366 Outcomes of Myeloablative Hematopoietic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia with Relapsed or Refractory Disease

2367 Reduced Intensity Conditioning (RIC) with Double Umbilical Cord Blood Transplantation Has Similar Outcomes Compared to RIC Transplantation From Related or Unrelated Adult Donors

2368 Unrelated Cord Blood Transplantation for Severe Acquired Aplastic Anemia Using a Reduced-Intensity Conditioning: High Graft Rejection but Good Survival

2369 The Impact of Donor Type In Patients with AML and High Risk Cytogenetic Aberrations

2370 Successful Treatment of High-Risk and Refractory Acute Myeloid Leukemia with haploidentical Stem Cell Transplantation Plus NK cell therapy

2371 Faster Registration on International Donor Registries and Shorter Time to Allogeneic Hematopoietic Stem Cell Transplantation After Having Found a Donor Confers Better Outcome In Acute Leukemia Patients

2372 Estimation of NOD2/CARD15 Haplotypes and Their Impact on the Outcome of Unrelated Donor Hematopoietic Stem Cell Transplantation for Acute Leukemia

2373 Donor KIR-Haplotype B Improved Relapse-Free Survival After Allogeneic Stem Cell Transplantation for Multiple Myeloma

2374 Umbilical Cord Blood Transplantion In Relapsed Multiple Myeloma

2375 Comparative Analysis of An Azacytidine Versus Azacytidine-HSCT Approach for the Treatment of Older Patients with AML/MDS

2376 Dose Finding Study of Lenalidomide as Maintenance Therapy In Multiple Myeloma After Allogeneic Stem Cell Transplantation

2377 The Association of the Polymorphisms of IMPDH1 Gene and Acute Graft-Versus-Host Disease After Related and Unrelated Hematopoietic Stem Cell Transplantation

2378 Allogeneic Stem Cell Transplantation From Unrelated One-Antigen HLA-Mismatched Donor, Increases Acute II-IV Gvhd Incidence without Interfering with Other Post-Transplant Complications

2379 Successful Allogeneic Hematopoietic Stem Cell Transplantation for Severe Inflammatory Bowel Disease – IL10 Receptor Deficiency May Serve as a Novel Therapeutic Paradigm

2380 Grafts From HLA-Identical Siblings Versus HLA-Allelic-Matched Unrelated Donors (10/10) In Patients Undergoing Allogeneic Stem Cell Transplantation Following Reduced-Intensity Conditioning Regimen

2381 Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor

2382 Implementation of An Alternative Donor Option Is Prerequisite for a Good Intention-to-Treat (ITT) In Patients In Need of Allogeneic Transplantation: Analysis of 410 Patients

2383 Flavopiridol Is An Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant

2384 HLA-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-CSF Mobilized Bone Marrow and Peripheral Blood Stem Cells

2385 Effect of Related and Unrelated Donor Haemopoietic Stem-Cell Transplantation on Outcome In Adults with High Risk Acute Leukemia: An Intention-to-Treat Analysis at a Single Center Institution 

2386 DEK/NUP214 Fusion Gene Predicts Good Outcome In Acute Myeloid Leukemia In Complete Remission After Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Results - Autologous Transplantation: Poster I

2387 A Phase I Study of Bortezomib During Maintenance Phase After High-Dose Melphalan and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma

2388 A Single-Centre Analysis by Intention to Treat with High Dose Chemotherapy and Autologous Stem Cell Rescue Following Second-Line Treatment In Patients with Hodgkin Lymphoma

2389 Significant Improvement In Overall Survival In Patients Who Underwent Autologous Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005

2390 The Role of Hematopoietic Cell Transplantation (HCT) for Burkitt Lymphoma: a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR)

2391 Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy

2392 Autologous Stem Cell Transplantation In Mantle Cell Lymphoma: The Experience of the French SFGM-TC Group

2393 High-Dose Therapy and Autologous Stem Cell Transplant (HD-ASCT) for Transformed Non-Hodgkin Lymphoma (NHL) In the Rituximab Era

2394 Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients

2395 Sufficient and Timely Autologous Stem Cell Harvest After Chemoimmunotherapy with Alemtuzumab In Combination with Bi-Weekly CHOP as First Line Treatment In Systemic Peripheral T-Cell Lymphomas (PTCL): a Feasibility Analysis From the First Randomized Trial In Systemic PTCL (ACT trial)

2396 Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma

2397 DMSO Reduction Strategies Reduce DMSO Induced Post Autologous Transplant Morbidity In Patients with Lymphoma and Myeloma –Results from an EBMT Non Interventional Prospective Study

2398 Clinical, Histomorphometric and Radiographic Evaluation of Dental Extraction Sockets Treated with Autologous Stem Cells

2399 High Rate of Complete Remission (CR) and Upgraded Response with Weekly Maintenance Bortezomib Post Single Autologous Peripheral Stem Cell Transplant (PSCT) In Patients with Multiple Myeloma. Results of a Phase II Prospective Study

2400 Outcome of High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplant In Myeloma Associated with AL Amyloidosis

2401 Cytoprotective Palifermin Allowed Melphalan Dose Escalation to 280mg/2 for Multiple Myeloma Patients with Normal Renal Function Receiving Autologous Stem Cell Transplantation (ASCT) - Final Results of a Phase 1 Trial

2402 Autologous Stem Cell Transplantion for Adolescents and Young Adults with Relapsed and Refractory Hodgkin Lymphoma

2403 High-Dose Melphalan for AL Amyloidosis: The Importance of Case Selection to Improve Clinical Outcomes

Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Poster II

2788 A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin’s Lymphoma

2789 Phase I-II Study of Dose Dense PEG-Filgrastim and GM-CSF as Support for Dose Dense CHOP-R Front Line Therapy for Aggressive Non-Hodgkin's Lymphoma (NHL)

2790 Pulse High-Dose Vorinostat Can Be Delivered with  Rituximab , Ifosphamide, Carboplatin, and Etoposide  In Patients with Relapsed Lymphoma: Final Results of a Phase I Trial

2791 Final Results of the RiPAD+C Regimen Including Velcade In Front Line Therapy for Elderly Patients with Mantle Cell Lymphoma. A Phase II Prospective Study of the GOELAMS Group

2792 Enhanced Delivery of Rituximab In Combination with Methotrexate-Based Blood-Brain Barrier Disruption for Patients with Newly Diagnosed Primary CNS Lymphoma

2793 Predictive Value for Event-Free Survival of Interim 18F-FDG-PET In Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim as First-Line Treatment: An Open-Label Clinical Trial In Spain

2794 Elderly Very Poor Performance Status Patients with Aggressive B Cell Lymphomas Can Gain Long Term Remissions with Intensive Chemotherapy with Encouraging Response Rates and Overall Survival (OS)

2795 Multicenter Phase II Study of the CyclOBEAP Regimen for Patients with Peripheral T-Cell Lymphoma with Analysis of Biomakers

2796 High Response Rate and Low Toxicity of Rituximab, Vinorelbine, Ifosfamide, Mitoxantrone and Prednisone Combination for the Treatment of Diffuse Large B Cell Lymphoma In First Relapse: Early Results of the R-NIMP GOELAMS Study

2797 Can a Dose-Dense RCHOP-Like Regimen Be Effectively Used In a Community Setting?  Results of a Phase II Study Employing Pegylated Liposomal Doxorubicin In Elderly (> age 60) or Cardiac Compromised (LVEF <45%) Patients with Diffuse Large B Cell Lymphoma (DLBCL)

2798 Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study

2799 Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies

2800 Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study

2801 Phase 1 Dose-Escalation Study of Multiple Dosing Schedules of the Investigational Drug MLN4924, a Nedd8-Activating Enzyme Inhibitor, In Patients with Relapsed and/or Refractory Multiple Myeloma or Lymphoma

2802 Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma

2803 A  Multi-Center Phase II Study (SAKK 36/06) of Single Agent Everolimus (RAD001) In Patients with Relapsed or Refractory Mantle Cell Lymphoma

2804 Intrathecal Chemotherapy Prophylaxis for CNS Relapse of DLBCL In the RCHOP Era: A Single Center Analysis

2805 R-CHOEP-14 x 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma /Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2-3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18-65 Years

2806 Bendamustine + Rituximab as Treatment for Elderly Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

2807 Ritonavir Based Highly Active Retroviral Therapy (HAART) Correlates with Early Neurotoxicity When Combined with ABVD Treated HIV Associated Hodgkin Lymphoma but Not Non-Hodgkin Lymphoma. A Retrospective Study

2808 Clinical Usefulness and Prognostic Value of Interim PET/CT for the Treatment of Peripheral T Cell Lymphomas

2809 Tailored Therapy In Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT, Can Lead to Modification and Safe Reduction In Therapy: Results of 134 Patients on the Israel National Hodgkin Study

2810 Rituximab Added to Aggressive Chemotherapy Improves the Outcome of Patients with Follicular Lymphoma, Grade 3 and Results In Survival Comparable to Diffuse Large B-Cell Lymphoma

2811 Resminostat In Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor

2812 Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP

2813 Clinicopathologic Characteristics and Outcome of Histiocytic and Dendritic Cell Neoplasms: A Single Institutional Experience

2814 Soluble Human Interleukin-2 Receptor (SIL-2R) as a Potential Predictor for Central Nervous System Relapse In Patients with Diffuse Large B-Cell Lymphoma In Rituximab Era: A 4.4-Year Follow up Analysis

2815 Non-Gastric Advanced MALT Lymphoma Demonstrated Worse Prognosis Than Gastric MALT Lymphoma Even Treated by Rituximab-Combined chemotherapy 

2816 A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma

2817 Contribution of PET /CT In the Design of the Involved Node Radiotherapy (INRT) Concept for Patients with Localized Hodgkin Lymphoma: Preliminary Results on 117 Patients

2818 Herpes Zoster (HZ) Complicating Bortezomib Therapy of Relapsed/Refractory Indolent B-Cell and Mantle Cell Lymphoma: An Analysis of Two Phase II Trials

2819 The Outcome of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP (R-CHOP) Is Not Predicted by 18-FDG-Positron Emission Tomography/Computerized Tomography (PET) Performed at Intermediate In-Course Evaluation, but Only by PET Assessed at the End of Therapy

2820 Anthracycline-Containing Regimens for Treatment of Follicular Lymphoma In Adults: Systematic Review and Meta-Analysis

2821 Prognostic Models to Predict Survival In Indolent and Aggressive Non-Hodgkin’s Lymphomas Associated with Hepatitis C Virus Infection: a Multicenter Italian Study on 1,043 Patients

2822 Gemcitabine-Based Salvage Chemotherapy as a Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for the Patients with Relapse of Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation

2823 EORTC 21012: Phase II Multicentre Study of Caelyx™ Monotherapy In Patients with Advanced Mycosis Fungoides Stage IIb, Iva and IVb with or without Previous Chemotherapy

2824 Short Course Adjuvant Chemotherapy for Localized Diffuse Large B-Cell Lymphoma After Complete Resection

2825 Rituximab Plus Gemcitabine and Oxaliplatin as Salvage Therapy In Patients with Relapsed/Refractory Mantle-Cell Lymphoma

2826 The Role of the Rituximab Partner Chemotherapy Regimen In Young Patients with Good-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Results of the 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group

2827 PVAG (Prednisone, Vinblastine, Doxorubicin and Gemcitabine) In Elderly Patients with Intermediate or Advanced Stage Hodgkin Lymphoma: Final Results of a Phase II Study of the German Hodgkin Study Group (GHSG)

2828 Lenalidomide In Patients with Relapsed or Refractory Hodgkin Lymphoma

2829 Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial

2830 Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes

2831 Long-Term Outcome for De Novo Lymphoblastic Lymphoma (LL) After Frontline Therapy with Hyper-CVAD Regimen and Variants

2832 A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3 Kinase P110δ, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies

2833 Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results

2834 Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin’s Lymphoma

2835 HIV-Associated Diffuse Large B Cell Lymphoma: Determinants of Survival In the Era of Rituximab and HAART

Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster I

2836 Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics

2837 Milatuzumab Improves Efficacy of Current Treatments for B-Cell Malignancies

2838 Non-Cognate Cytotoxic T Cells Can Be Retargeted Against CD20 Positive Tumour Cells Using [Fab' x MHC Class I/Peptide] Conjugates

2839 P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity In Primary CLL Cells and Is Synergistic with Fludarabine at Low Concentrations

2840 The Novel Organic Arsenical, Darinaparsin (ZIO-101), Induces Apoptosis through AKT and MEK/ERK Pathways In Hodgkin Lymphoma (HL) and T-Cell Lymphoma (TCL) Cell Lines

2841 A Therapeutic Vaccine Using Activated Tumor Cells by Salmonella Infection and Interleukin-2 Induces Antitumor Immunity In B-Cell Lymphoma

2842 Antitumor Activity of Amphibian Ribonucleases,  Onconase and R-Amhinase, on Tumor Cells From B-Cell Lymphoproliferative Disorders

2843 Fusion Proteins of Ligands for NKG2D and CD20-Directed ScFvs Sensitize Lymphomas for NK Cell-Mediated Lysis

2844 Resveratrol Induces Cell Growth Arrest and Cell Death of Adult T-Cell Leukemia Cells Via Deacetylation of STAT3 by SIRT1

2845 Lenalidomide Induces Capping of CD20 and Cytoskeleton Proteins to Enhance Rituximab Immune Recognition of Malignant B-Cells

2846 The Novel Bispecific Antibody [(CD20)2xCD16] Efficiently Triggers Lysis of Neoplastic B Cells

2847 Bortezomib Induces Caspase-9-Mediated Apoptosis through Activation of the BH3-Only Proteins Noxa, Bik and Puma In Both ALK-Positive and ALK-Negative Anaplastic Large Cell Lymphoma Cells

2848 Combined Inhibition of Janus and Aurora Kinases by the Novel Small Molecule Inhibitor AZD1480 Induces Cell Death  and Downregulates PD-L1 and PD-L2 Expression In Hodgkin Lymphoma

2849 [18F]FLT Is Superior to [18F]FDG to Early Predict Response to Specific Inhibitors of NPM-ALK-Dependent Pathways In a Human ALCL Xenograft Model

2850 The Histone Deacetylase Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction

2851 The Pan-Deacetylase Inhibitor Panobinostat Downregulates HIF-1α and VEGF and, Synergizes with Everolimus In Hodgkin Lymphoma Cell Lines

2852 Inhibition of Tak-1 by AZ-Tak1 Impairs NF-κB Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma

2853 Combining Mtor Inhibitors with Rapa-Resistant T Cells: a Two-Pronged Approach to Tumor Elimination

2854 Direct Growth Inhibition of Both Mouse and Human B Cell Lymphomas by CpG Oligodeoxynucleotides

2855 Targeting the PI3K/AKT/Survivin Pathway with Ritonavir In Therapy-Resistant Mantle Cell Lymphoma

2856 Treatment with Histone Deacetylase 6-Specific Inhibitor WT-161 Disrupts hsp90 Function, Abrogates Aggresome Formation and Sensitizes Human Mantle Cell Lymphoma Cells to Lethal ER Stress Induced by Proteasome Inhibitor Carfilzomib

2857 Purified, Fermented, Extract of Triticum Aestivum Has Significant Independent Lymphomacidal Activity and Augments the Activity of Rituximab

Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II

2858 A Two-Stage Phase Ib Study to Investigate the Pharmacokinetics, Safety and Tolerability of Subcutaneous Rituximab In Patients with Follicular Lymphoma as Part of Maintenance Treatment
 
2859 Outcomes In the Pre-Rituximab and Post-Rituximab Eras In Post-Transplantation Lymphoproliferative Disorders (PTLD) In Adult Solid Organ Transplant Recipients
 
2860 Interim-Positron Emission Tomography with [18F]Fluorodeoxyglucose (interim-PET) Evaluation In Mediastinal Lymphoma Including Hodgkin Lymphoma (HL) and Primary Mediastinal Large B-Cell Lymphoma (PMBL)
 
2861 Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib In Heavily Pretreated Patients with Relapsed/Refractory Lymphomas: Preliminary Results of a Phase II Trial
 
2862 Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin’s Lymphoma
 
2863 Efficacy of Denileukin Diftitox Retreatment In Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response
 
2864 Interferon Maintenance Prolongs Remission Duration After Rituximab-Containing Induction In First-Line Advanced Stage Follicular Lymphoma Patients – a Retrospective Analysis of the German Low-Grade Lymphoma Study Group (GLSG)
 
2865 A Phase I Clinical Trial of Treatment of B-Cell Malignancies with Autologous Anti-CD19-CAR-Transduced T Cells
 
2866 90Υ-Ibritumomab Tiuxetan Followed by Rituximab Is a Safe Treatment Option for Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin s Lymphoma
 
2867 The Addition of Rituximab to CVP (Bagley) + Interferon-α as Induction Regimen, Significantly Increases Complete Remission Rates and Progression Free Survival In Intermediate-High Risk Follicular Lymphoma Patients (LNH-pro vs. LNH-pro-05 trial)
 
2868 Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – Updated Results with Encouraging Progression Free Survival (PFS) Data From a Phase II Study In Patients with Relapsed/Refractory Indolent NHL (iNHL)
 
2869 Protective Effect of Rituximab Against Lymphoma Risk In HIV-Associated Multicentric Castleman Disease
 
2870 The Rituximab and IVIG Related IgM Flare In Waldenstrom’s Macroglobulinemia Is Associated with Monocytic Activation of Fcgriia Signaling, and Triggering of IL-6 Release by the PI3K/AKT and MAPK Pathways
 
2871 Prospective, Multicenter Phase I–II Pilot Trial to Evaluate Efficacy and Safety of Lenalidomide Plus Rituximab-CHOP21 (LR-CHOP21) for Elderly Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis of the Intergruppo Italiano Linfomi (IIL) REAL07 Study
 
2872 Phase 1 Study of Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Japanese Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
 
2873 Pretreatment EBV-DNA Copy Number Is Predictive for Response to SMILE Chemotherapy for Newly-Diagnosed Stage IV, Relapsed or Refractory Extranodal NK/T-Cell Lymphoma, Nasal Type: Results of NKTSG Phase II Study
 
2874 CD20-Negative Phenotypic Change In B-Cell Lymphoma Cells After Using Rituximab: Possibility of a Particular Clinicopathologic Phenomenon Post-Rituximab Extranodal CD20-Negative Lymphoma
 
2875 Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients
 
2876 Indolent B-Cell Lymphomas Treated Upfront with Antiviral Therapy: a Series of 13 Patients
 
2877 Clinical Activity of Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients
 
2878 Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL
 
2879 A Phase II Study of Gemcitabine, Rituximab, and Oxaliplatin In Combination for Relapsed/Refractory Non-Hodgkin's Lymphomas
 
2880 Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 µg/m²/d Is Tolerable and Highly Effective
 
2881 Rituximab Is Associated with Prolonged Immunoglobulin Deficiency In Newly Diagnosed Patients with Aggressive B-Cell Lymphoma Receiving Immunochemotherapy
 
2882 Median Absolute Lymphocyte Count Independently Predicts Survival of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-Chemotherapy: Analysis of 651 Patients Included In the Czech Lymphoma Project
 
2883 Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy

 

Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Immunotherapeutics and Small Molecule Inhibitors

283 Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma

284 Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592)

285 Multicenter Phase II Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, In Relapsed Patients with Adult T-Cell Leukemia-Lymphoma (ATL)

286 In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study

287 A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas

288 Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin Lymphoma - Biology, excluding Therapy: Clinical Correlations

319 Concurrent BCL2 and MYC Translocations In a Prospective Cohort of Diffuse Large B-Cell Lymphomas

320 Interim [18F]Fluorodeoxyglucose Positron Emission Tomography SUVmax Reduction Is Superior to Visual Analysis to Predict Early patient’s Outcome In Diffuse Large B-Cell Lymphoma

321 Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas

322 Prognostic Factors and Long Term Outcome of 138 Adults with Systemic Anaplastic Large-Cell Lymphoma: a Retrospective Study by the Groupe d’Etude Des Lymphomes De l’Adulte (GELA)

323 Evidence of Long Latency Periods Prior to Development of Mantle Cell Lymphoma

324 A miRNA Risk Score for the Prediction of Response to Rituximab-CHOP Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma

Clinical Results - Alternative Donor Transplantation II

361 Interactions Between Total Nucleated and CD34 Cell Dose and Their Impact on Outcomes After Single and Double Unrelated Cord Blood Transplantation for Patients with Hematological Malignancies. An Analysis on Behalf of Societe' Française De Greffe De Moelle Et Therapie Cellulaire (SFGM-TC) and Eurocord

362 Mesenchymal Stem Cell (MSC) Based Cord Blood (CB) Expansion (Exp) Leads to Rapid Engraftment of Platelets and Neutrophils

363 Matched Unrelated Donor Transplantation Is Curative In Selected Patients with Diffuse Large B Cell Lymphoma:  A Report of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT)

364 Allogeneic Hematopoietic Cell Transplantation (AHCT) for Primary Cutaneous T Cell Lymphoma (CTCL): a Center for International Blood and Marrow Transplant Research (CIBMTR) Review

365 Follow-up of 12,559 Unrelated Donors of Peripheral Blood Stem Cells or Bone Marrow

366 Health-Related Quality-of-Life Among Adult Matched Unrelated Stem Cell Donors: A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Randomized Trial of Marrow Versus PBSC Donation

Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Hodgkin and Primary Mediastinal Large B-cell Lymphoma

415 A Randomized Phase III Trial of ABVD Vs. Stanford V +/- Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496)

416 Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496

417 Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials

418 Feasibility and Efficacy of ABVD In Elderly Hodgkin Lymphoma Patients: Analysis of Two Randomized Prospective Multicenter Trials of the German Hodgkin Study Group (HD10 and HD11)

419 Final Analysis: Phase II Study of Oral Panobinostat In Relapsed/Refractory Hodgkin Lymphoma Patients Following Autologous Hematopoietic Stem Cell Transplant

420 Sequential Dose-Dense RCHOP Followed by ICE Consolidation (MSKCC protocol 01-142) without Radiotherapy for Patients with Primary Mediastinal Large B Cell Lymphoma

Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Novel Immune-Mediated Approaches

421 Antitumor Activity of An RNA-Based Agonist of TLR7 and 8 In Preclinical Models of Hematological Malignancies

422 Immunomodulation of NK Cells through 4-1BB (CD137) to Improve the Anti-Lymphoma Activity of Rituximab: Antibody-Based Anti-Lymphoma Synergy 

423 A Complement-Dependent Cytotoxicity-Enhancing Anti-CD20 Antibody Mediating Potent Antitumor Activity In the Humanized NOD/Shi-Scid, IL-2Rγnull Mouse Lymphoma Model

424 Ex Vivo Generated Donor Central Memory CD8 T Cells, Previously Shown to Enhance Engraftment of Allogeneic Bone Marrow, Also Exhibit Significant GVL Activity without Causing Gvhd In An In Vivo b Cell Lymphoma Model

425 The Bispecific Anti-CD20/CD22 Antibody (Bs20x22) Has More Lymphomacidal Activity Than the Parent Antibodies Both Alone or In Combination

426 A Novel 3D Co-Culture System for Isolation and Amplification of Primary Liquid Cancer Cells

421 Antitumor Activity of An RNA-Based Agonist of TLR7 and 8 In Preclinical Models of Hematological Malignancies

422 Immunomodulation of NK Cells through 4-1BB (CD137) to Improve the Anti-Lymphoma Activity of Rituximab: Antibody-Based Anti-Lymphoma Synergy 

423 A Complement-Dependent Cytotoxicity-Enhancing Anti-CD20 Antibody Mediating Potent Antitumor Activity In the Humanized NOD/Shi-Scid, IL-2Rγnull Mouse Lymphoma Model

424 Ex Vivo Generated Donor Central Memory CD8 T Cells, Previously Shown to Enhance Engraftment of Allogeneic Bone Marrow, Also Exhibit Significant GVL Activity without Causing Gvhd In An In Vivo b Cell Lymphoma Model

425 The Bispecific Anti-CD20/CD22 Antibody (Bs20x22) Has More Lymphomacidal Activity Than the Parent Antibodies Both Alone or In Combination

426 A Novel 3D Co-Culture System for Isolation and Amplification of Primary Liquid Cancer Cells

Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Immunotherapy for Indolent Lymphoma

427 Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)

428 A Phase 2, Double-Blind, Placebo-Controlled Trial of Rituximab + Galiximab Vs Rituximab + Placebo In Advanced Follicular Non-Hodgkin’s Lymphoma (NHL)

429 Vaccination with IgM but Not IgG Idiotype Prolongs Remission Duration In Follicular Lymphoma Patients

430 Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial

431 Phase II/III Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab (R-CHOP) Versus Biweekly CHOP with Rituximab (R-Bi-CHOP) In Untreated Advanced-Stage Indolent B-Cell Lymphoma: Japan Clinical Oncology Group (JCOG) 0203 Trial

432 Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study

Non-Hodgkin Lymphoma - Biology, excluding Therapy: Biologic Mechanisms of Lymphomagenesis

463 Serological Identification of HSP105 as a Novel Non-Hodgkin Lymphoma Therapeutic Target

464   miR155 DOWNREGULATES EXPRESION of HGAL and INCREASES LYMPHOMA CELL MOTILITY

465 The Role of Mir-150 as a Tumor Suppressor In Malignant Lymphoma

466 Follicular Lymphoma-Like B Cells In Healthy Individuals Are Released From Pretumoral Niches Established In Secondary Lymphoid Tissues

467 Ccytosporone-B Induces NR4A1 Meditated Apoptosis In Aggressive Lymphoma Cells

468 A BAFF-R Mutation Associated with Non-Hodgkin Lymphoma Exhibits Altered TRAF Binding and Reveals New Insights Into Proximal BAFF-R Signaling

Clinical Results - Allogeneic Matched Related Donor Transplantation

523 Matched Sibling Transplants for Aplastic Anemia: Survival Advantage for Marrow Vs Peripheral Blood Transplants , In All Age groups

524 Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial:  No Difference In Results Between B Cell Immunophenotypic Subgroups

525 Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma

526 Tandem Autologous Stem Cell Transplants (auto-auto) with or without Maintenance Therapy Versus Single Autologous Transplant Followed by HLA-Matched Sibling Non- Myeloablative Allogeneic Stem Cell Transplant (auto-allo) for Patients (pts) with High Risk (HR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 Trial

527 Genetic Variability In the Transcriptional Factor EP300 Strongly Influences the Clinical Outcome of Allogeneic Stem Cell Transplantation (Allo-SCT)

528 Final Report of a Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation

Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Aggressive Lymphoma and Radioimmunotherapy

589 R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Long-Term Follow-up of Intergroup E4494 / C9793

590 R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433

591 Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515

592 Adapted Management of EBV Reactivation After Solid Organ Transplantation: An Effective Prevention of Post Transplantation Lymphoproliferative Disorders (PTLD). Results of the Largest Prospective Study on 251 Patients

593 90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma. First Results from an International Phase II Clinical Trial

594 90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin’s Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

Non-Hodgkin Lymphoma - Biology, excluding Therapy: Gene Profiling/Signaling

631 Comparative Genomic Identification of Unique Signal Transduction Pathways and Targets In Pediatric Burkitt Lymphoma (PBL)

632 Recurrent DNA Mutations In Non-Hodgkin Lymphomas Reveal Candidate Therapeutic Targets

633 Massively Parallel Mate Pair DNA Library Sequencing for Translocation Discovery:  Recurrent t(6;7)(p25.3;q32.3) Translocations In ALK-Negative Anaplastic Large Cell Lymphomas

634 Over 30% of Patients with Splenic Marginal Zone Lymphoma Express Distinctive Antigen Receptors Utilizing a Single Immunoglogulin Variable Gene: Implications for the Origin and Selection of the Neoplastic Cells

635 Integrative Analysis Reveals Multiple Alterations of p53 Signaling Pathway Components In Primary Diffuse Large B-Cell Lymphomas

636 Clinical Translation of a Prognostic Follicular Lymphoma Signaling Profile

Clinical Results - Autologous Transplantation: Lymphoma

685 No Benefit of First-Line Rituximab (R) - High-Dose Therapy (R-HDT) Over R-CHOP14 for Young Adults with Diffuse Large B-Cell Lymphoma. Preliminary Results of the GOELAMS 075 Prospective Multicentre Randomized Trial

686 A Multi-Center Prospective Randomized Study Comparing Ibritumomab Tiuxetan (Zevalin) and High-Dose BEAM Chemotherapy (Z-BEAM) Vs. BEAM Alone as the Conditioning Regimen Prior to Autologous Stem-Cell Transplantation In Patients with Aggressive Lymphoma; Possible Advantage for  Z-BEAM In Low-Risk Patients

687 Autologous Stem Cell Transplantation Is a Curative Treatment Modality for Relapsed or Refractory Follicular Lymphoma, and Both Recent Rituximab Exposure and Follicular Lymphoma International Prognostic Index (FLIPI) 0-1 Scores Predict Improved Outcome

688 Is There Still a Place for Total Body Irradiation (TBI) In the Conditioning Regimen of Autologous Stem Cell Transplantation In Mantle Cell Lymphoma ?: a Retrospective Study From the Lymphoma Working Party of the EBMT

689 Autologous (auto) Versus Allogeneic (allo) Hematopoietic Cell Transplantation (HCT) for T-NHL: A CIBMTR Analysis 

690 Gemcitabine, Busulfan and Melphalan (GemBuMel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity In Refractory Hodgkin’s Lymphoma (HL) Patients Receiving An Autologous Stem-Cell Transplant (ASCT): A Contemporaneous Comparison with BEAM and Busulfan/Melphalan (BuMel

Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Therapy of Hodgkin Lymphoma and Indolent Non-Hodgkin Lymphoma

763 Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma:  Results of CALGB 50202

764 Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial

765 Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

766 AHOD0031: A Phase III Study of Dose-Intensive Therapy for Intermediate Risk Hodgkin Lymphoma: A Report From the Children’s Oncology Group

767 A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Lymphoma (HL)

768 Final Results of a Randomized Phase 2 Multicenter Study of Two Bortezomib Schedules In Patients with Recurrent or Refractory Follicular Lymphoma. Groupe d’Etude Des Lymphomes De l’Adulte (GELA) Study FL-05

Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Preclinical Advances in Mantle Cell Lymphoma

769 A Novel Pro-Survival Function of Cyclin-D1 Underlies Its Oncogenic Role and Potential as a Therapeutic Target In Mantle Cell Lymphoma 

770 Rational for the Use of a Targeted-Therapy Using ABT-737 In Mantle-Cell Lymphoma.

771 Synergistic Effects of a Novel Water-Soluble Small Molecule, ON 013105, and Rituximab on Mantle Cell Lymphoma In Vitro and In Vivo

772 Dual Inhibition of mTORC1/mTORC2 Induces Apoptosis of Mantle Cell Lymphoma by Preventing Rictor Mediated AKTS473 Phosphorylation by Potentiating AKT2-PHLPP1 Association

773 Halofuginone Induces Post-Transcriptional Down-Regulation of Cyclin D1, Cell Cycle Arrest and Apoptosis In Mantle Cell Lymphoma Cells through Activation of Integrated Stress Response Pathways

774 B-Cell Lymphoma In Eu-Mir-17~92 Transgenic Mice

Non-Hodgkin Lymphoma - Biology, excluding Therapy: Advanced Technology in Non-Hodgkin Lymphoma Genetics

799 TNFRSF14 and EZH2 Mutations, Chr2p Gain and Copy Number Changes Targeting Genes Whose Proteins Interact with the Microenvironment In Transformed Follicular Lymphoma

800 Comparing MicroRNA Expression In Aggressive and Indolent Non-Hodgkin Lymphomas Identifies a Prognostic Signature for Mantle Cell Lymphoma

801 Cytogenetic Abnormalities In a Cohort of 171 Patients with Waldenström Macroglobulinemia Before Treatment : Clinical and Biological Correlations

802 TNFAIP3 (A20) Genetic Alterations In EBV Associated AIDS Related Lymphomas 

803 Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma

804 Identification of Genes Frequently Mutated In FL and DLBCL with Transcriptome, Genome and Exome Sequencing

Clinical Results - Allogeneic Matched Related Donor Transplantation: Poster I

3500 Comparison of 5-Azacytidine Versus Allogeneic Hematopoietic Cell Transplantation In Elderly (≥ 60 years) Patients with De Novo High-Risk MDS - a Retrospective Matched Pair Analysis

3501 Allogeneic Hematopoietic Stem-Cell Transplantation In Early Phase Might Overcome the Adverse Prognosis of Acute Myeloid Leukemia with Translocation t(6;9)(p23;q34)/DEK-NP214(CAN) Rearrangement. A Retrospective Analysis From the Acute Leukemia Working Party of EBMT

3502 Lenalidomide Maintenance Following Non Myeloablative Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma: Results of the HOVON 76 Study

3503 Prognostic Impact of Pretransplant Transfusion Amount on Outcome After Allogeneic Stem Cell Transplantation In Adult Patients with Severe Aplastic Anemia

3504 A Pilot Study of Reduced Toxicity Conditioning (RTC) with Busulfan (Bu), Fludarabine (Flu), and Alemtuzumab Followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Sustained Mixed Donor Chimerism In Patients with Symptomatic Sickle Cell Disease (SCD)

3505 Long-Term Follow-up of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Severe Paroxysmal Nocturnal Hemoglobinuria

3506 Transplant Conditioning Regimens and Outcomes After Allogeneic Hematopoietic Cell Transplantation (HCT) In Children and Adolescents with Acute Lymphoblastic Leukemia (ALL)

3507 Differential Gene Expression Associated with Chronic Myeloid Leukemia (CML) Progression Predicts Relapse and Survival Prior to Allogeneic Transplantation In Chronic Phase CML Patients

3508 Comparison of Outcomes After Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) In 73 Patients with Follicular Lymphoma (FL), Transformed Follicular Lymphoma (TL), or De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Favorable Outcome for TL Similar to FL

3509 Significant Improvement In Day 100 and 1-Year Overall Survival In Patients Who Underwent Myeloablative Allogeneic Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005

3510 Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy

3511 Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia In First Complete Remission: A Systematic Review and Meta-Analysis

3512 A Comparison of Two Different Reduced Intensity Conditioning (RIC) Allograft Strategies In Patients with Multiple Myeloma, An EBMT Analysis

3513 Long-Term Outcome Associated with Current Allogeneic Stem Cell Transplantation Procedures In Younger Adults with Adverse-Risk AML In First CR – A Real-Life Transplant Versus No-Transplant Analysis of the Acute Leukemia French Association (ALFA)

3514 RESULTS of Allogeneic TRANSPLANTATION for Polycythemia VERA and Essential Thrombocythemia 

3515 Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia

3516 Myeloablative Bone Marrow Transplantation in Young Adults with Sickle Cell Disease: the French Experience

3517 The Impact of Center Experience on Results of Reduced Intensity – Allogeneic Hematopoietic Stem Cell Transplantation. A Survey From the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT)

3518 Related Myeloablative Stem Cell Transplantation (SCT) to Cure Sickle Cell Anemia (SCA): Update of French Results

3519 Allogeneic Transplant In Children with Severe Aplastic Anemia – Excellent Outcomes with the Use of a Fludarabine Based Conditioning Regimen

3520 Rituximab In Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Chronic Lymphocytic Leukemia with Fludarabine + Total Body Irradiation Conditioning: Results of a Phase II Prospective Multicenter Study (ITAC 02-02)

3521 G-CSF-Primed Allogeneic-BMT Following Reduced Intensity Conditioning (RIC) Regimen for Patients with AML. Rapid Engraftment, Low Incidence of Chronic Gvhd (cGVHD) and Good Outcome for Patients In 1st Complete Remission (CR), but Not for More Advanced Cases

3522 Primed-G-CSF BMT for Children with Fanconi Anemia (FA) Using Mycophenolate Mofetil (MMF) and Cyclosporine-A for Gvhd Prophylaxis: Rapid Neutrophil Engraftment, Less Mucositis and Low Incidence of Chronic Gvhd

Clinical Results - Alternative Donor Transplantation: Poster II

3523 Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning

3524 Unrelated Umbilical Cord Blood Transplantation for Patients with Primary Immunodeficiency:  A Report From the Registry of the Japan Cord Blood Bank Network

3525 Total Outpatient Care for Myeloablative Unrelated Donor Hematopoietic Cell Transplantation: A Safe and Effective Alternative to Standard In-Patient Care

3527 A Decision Analysis of Unrelated Hematopoietic Stem Cell Transplantation for Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia In First Remission Who Lack An HLA-Matched Sibling

3528 Allograft After Pediatric-Inspired Therapy Does Not Improve Young patient’s Outcome with High Risk Philadelphia- Chromosome-Negative Acute Lymphoblastic Leukemia (Ph-ALL).  A Single Center Report

3529 Haploidentical Transplantation In Adults ≥ 66 Years of Age

3530 Use of Targeted Lymphocyte Depletion as a Personalized Approach to Improve Engraftment and Disease Control Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Unrelated Donors

3531 Reduced Intensity Versus Myeloablative Conditioning in  Adults with Acute Myeloid Leukemia  Transplanted with Umbilical Cord Blood

3532 Similar Overall Survival and Toxicity After CB Transplanation with Co-Infusion of  CD34+ Cells From a Third Party Donor Compared to Myeloablative MUD Stem Cell Transplantation In High Risk Patients

3533 Full Haplotype Mismatch Stem Cell Transplantation: Myeloablative with T-Cell Depletion Vs. Reduced Intensity Conditioning without T-Cell Depletion

3534 Role of Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma Relapsing After Autograft: a Donor Versus No Donor Analysis

3535 Reduced Intensity Conditioning In Children Undergoing Unrelated Umbilical Cord Blood Transplantation for Non-Malignant Diseases: Preliminary Results Demonstrate a High Rate of Engraftment and Low Incidence of Gvhd

3536 Allogeneic Stem Cell Transplantation (alloSCT) and Donor Lymphocyte Infusion (DLI) In Patients with Non-Hodgkin Lymphoma (NHL) Who Experienced Relapse or Progression After Autologous Stem Cell Transplantation (autoSCT): Retrospective Analysis From the Korean Society of Blood and Marrow Transplantation

3537 Outcomes of Patients Treated with Matched and Mismatched Unrelated Donors Using High-Resolution HLA Typing at 12 Loci

3538 Hematopoietic Cell Transplantation from an HLA-Mismatched Familial Donor After Reduced-Intensity Conditioning Containing Busulfan, Fludarabine, and Antithymocyte Globulin for Patients with Acute Leukemia and Myelodysplastic Syndrome

3539 Impact of Donor Source and Match on Outcome of Allogeneic Hematopoietic Cell Transplantation with Reduced Intensity Conditioning

3540 Outcome of Patients Aged ≥60 After Allogeneic Hematopoietec Cell Transplantation:  Age Has No Impact on Survival

3541 Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies

3542 Outcome of Hodgkin’s Lymphoma Patients After Reduced-Intensity Allogeneic Stem Cell Transplantation: Complete Remission Status Has the Most Relevant Clinical Impact along with Extranodal Disease and C-Reactive Protein Before Transplant

3543 Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Cerebral Variant Adrenoleukodystrophy:  A Modern, Single-Institution Experience

3544 Allogeneic and Autologous Transplantation In Patients with Aggressive B- and T-Cell Lymphomas

3545 Comparison of Single Versus Multiple Unit Umbilical Cord Blood Transplantation for Adult Hematologic Malignancy Patients

3546 Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for the Treatment of Children with Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) In First Remission (CR1)

3547 Allogeneic Hematopoietic Stem Cell Transplantation Using An Intravenous Busulfan Based Myeloablative Conditioning without Total Body Irradiation for Pediatric Patients with Acute Lymphoblastic Leukemia

3548 Use of IL15 Stimulated, CD3/19 Depleted Transplants From Haploidentical Donors In Pediatric Malignancies

3549 Validation of the Cord Blood (CB) APGAR Score System to Predict Neutrophil Engraftment of Plasma Depleted CB Products

3550 Minimal Residual Disease Status at Day +100 Post Allogeneic Hematopoietic Stem Cell Transplantation Is a Powerful Predictor for Post-Transplant Outcome In Patients with High Risk Acute Leukemia

3551 Factors That Contribute to Long-Term Survival In Patients with Leukemia Not In Remission at Allogeneic Hematopoietic Cell Transplantation

3552 Haploidentical Hematopoietic Stem Cell Transplantation In Hematologic Malignancies with G-CSF Mobilized Bone Marrow Plus Peripheral Blood Stem Cells Grafts without T Cell Depletion: a Single Center Report of 29 Cases

Clinical Results - Autologous Transplantation: Poster III

3553 High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis

3554 Trend towards Improved Day 100 and 2-Year Survival After SCT for AL Amyloidosis: Outcomes Before and After 2006

3555 Comparison of High Dose Chemotherapy with Autologous Stem Cell Rescue (ASCT) Versus Consolidation Chemotherapy for Patients < 60 with Cytogenetically Normal AML (CN-AML) and Flt3 ITD

3556 Impact of the Presence of An Internal Tandem Duplicate of FlT3 Receptor (ITD) on the Outcome of Adult Patients with Acute Myelocytic Leukemia (AML) Autografted In First Remission (CR1)Norbert-Claude Gorin, Myriam Labopin, Jordi  Esteve, and Mohamad Mohty, on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

3557 Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicitng Outcome In Over 400 Patients

3558 Post-ASCT Consolidative Immunotherapy with RITUXIMAB, rINF-a2b and rIL2 In Poor-Risk DLBCL: Results of a Phase II Study

3559 High Dose Therapy with Autologous Stem Cell Transplantation Vs Standard Dose Chemotherapy In Multiple Myeloma: A Meta-Analysis

3560 Outcomes In Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation Using Intravenous Busulfan and Melphalan: A Matched Comparison to a Double Autologous Transplant Strategy

3561 Autologous Stem Cell Transplantation Is Feasible and of Potential Benefit In Very Elderly Patients with Lymphoma and Limited Comorbidities

3562 Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 Patients

3563 Autologous Stem Cell Transplantation In Mantle Cell Lymphoma: Total Body Irradiation (TBI) Plus Cyclophosphamide (or Melphalan) Is Not Superior to BEAM, A Single Institution Experience

3564 Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma

3565 Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy-Associated T-Cell Lymphoma: a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

3566 Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

3567 Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant

3568 Reapplication of High-Dose Chemotherapy with Melphalan Followed by Autologous Hematopoietic Stem Cell Transplantation as Salvage Therapy for Patients with Relapsed Multiple Myeloma

3569 Outcome of  Patients with Relapsed/Refractory AIDS-Related Lymphoma In the AIDS Malignancy Consortium (AMC) 1997-2008

3570 Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance

3571 Killer Cell Immunoglobulin-Like Receptor (KIR) Ligands Predict Outcomes of Autologous Stem Cell Transplantation for AML

3572 Comparison of Troponin T and N-Terminal-Pro-Brain Natriuretic Peptides In Two Models of Treatment Related Mortality In AL Amyloidosis Patients Following Autologous Stem Cell Transplantation

3573 A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients 

Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster II

3915 Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263

3916 Novel Fc-Engineered Antibodies to CD37 with Pro-Apoptotic and Enhanced ADCC Activity

3917 Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenografts, and Primary Tumor Cells Derived From Patients with B-Cell Non-Hodgkin Lymphoma (NHL)

3918 The Nucleoside Analogue Acadesine Exerts Antitumoral Activity and Cooperates with Conventional Agents In In Vitro and In Vivo Models of Mantle Cell Lymphoma

3919 Lestaurtinib (CEP701) Inhibits Proliferation and Activates Apoptosis In Hodgkin Lymphoma Cells through Inhibition of the JAK/STAT Signaling Pathway

3920 MDM2 Antagonist Nutlin-3 Enhances Bortezomib-Mediated Mitochondrial Apoptosis In TP53-Mutated Mantle Cell Lymphoma

3921 Mimetic Peptide to CDK Inhibitor p16 INK4a Induces Cell Death In Mantle Cell Lymphoma Cells: A New Strategy to Eradicate Minimal Residual Disease

3922 A Small Molecule PLK1 Inhibitor, MLN0905, Induces An Anti-Tumor Response In Human Models of Diffuse Large B-Cell Lymphoma

3923 Targeted Depletion of B-Cell Subsets by Anti-CD22 and Anti-CD79bAntibody Drug Conjugates: Illumination of the Mechanism of Action through Pharmacodynamic Biomarkers

3924 In Vivo Efficacy of Peptide-Derived B Cell Receptor (BCR) Targeted Therapy In a Disseminated Burkitt´s Lymphoma Xenograft Modell

3925 Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101vs. the Type I CD20 Antibodies Rituximab and Ofatumumab

3926 CAL-101, a Potent Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3kinase, Attenuates Pathway Signaling, Induces Apoptosis, and Overcomes Signals From the Microenvironment In Cellular Models of Hodgkin Lymphoma

3927 Stromal Cross-Presentation and Host Interferon-γ Signaling and Are Required for Elimination of Antigen-Loss Variants of High-Grade B Cell Lymphomas: Implications for Adoptive T Cell Therapy

3928 Genetically Reengineered K562 Cells Significantly Expand Cord Blood (CB) Natural Killer (NK) Cells Ex-Vivo Expanded with Increased NK Cell Activation and Cytolytic Activity Both In-Vitro and In-Vivo: Potential Use In Adoptive Cellular Immunotherapy (ACI)

3929 Role of Microenvironment In Mantle Cell Lymphoma: IL-6 as An Important Survival Factor for Tumor Cells

3930 AT9283, a Novel Pan-Aurora/JAK-2 Kinase Inhibitor Suppresses Tumor Growth In Aggressive B-Cell Non-Hodgkin’s Lymphoma

3931 TRU-016, An Anti-CD37 SMIPTM Biologic, In Combination with Other Therapeutic Drugs In Models of Non-Hodgkin’s Lymphoma

3932 Small Molecule Inhibitor of ITK Disrupts TCR Signaling and Demonstrates Anti-Tumor Efficacy

3933 Addition of Rituximab to MLN8237 An Aurora A Kinase Inhibitor Plus Vincristine or Docetaxel Has Synergistic Anti-Tumor Activity In a Mouse Model of Aggressive B-Cell Non-Hodgkin’s Lymphoma

3934 The Bioactive Polyphenol Curcumin (diferuloylmethane) In Human Apolipoprotein A-1 Nanodisks Enhances Apoptosis and G1 Cell Cycle Arrest In Mantle Cell Lymphoma Compared with Free Curcumin

3935 Rituximab Directly Decreases T Cell Activation, Both In Vivo and In Vitro

3936 Panobinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) In Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines

3937 The Combination of Histone Deacetylase Inhibitors and Hypomethylating Agents Exhibits Marked Synergy In Preclinical Models of T-Cell Lymphoma

3938 Histone Deacetylase Inhibitors Potentiate the Lethality of the Irreversible Proteasome Inhibitor Carfilzomib In Mantle Cell Lymphoma Cells In Vitro and In Vivo

3939 MLN2238, a Novel and Potent Proteasome Inhibitor, Induces Caspase-Dependent Cell Death, Cell-Cycle Arrest, and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Chemotherapy Sensitive or Resistant B-Cell Lymphoma Cell Lines

3940 Generation and Characterization of a Novel CD19-CherryLuciferase (CD19CL) Mouse Model: A New Fluorescent/Bioluminescent Model for the Study of B-Cell Development and Lymphomagenesis

3941 Epratuzumab (Humanized Anti-CD22 MAb) Conjugated with SN-38, a New Antibody-Drug Conjugate (ADC) for the Treatment of Hematologic Tumors:  Preclinical Studies Alone and In Combination with Veltuzumab, a Humanized Anti-CD20 Mab

Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III

3942 Phase I Study of a New Humanized Anti-CD20 Monoclonal Antibody (LY2469298) in Japanese Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL) Pretreated with Rituximab-Containing Regimen

3943 Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies

3944 Specific Chemotherapy and Rituximab In HIV-Infected Patients with Burkitt’s Leukemia or Lymphoma. Results of a German-Spanish Study and Analysis of Prognostic Factors

3945 Maintenance Rituximab Every 2 Months for 2 Years Is Effective and Well Tolerated In Patients with Follicular Lymphoma with Both Standard or Rapid Infusion: Updated Results From the Phase IIIb MAXIMA Study

3946 Update on a Prospective Study Evaluating the Safety and Efficacy of Combination Therapy with Fludarabine, Mitoxantrone and Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan and Maintenance Rituximab as Front Line Therapy for Patients with Indolent Lymphomas

3947 Phase II Study of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis

3948 Central Nervous System Events In Patients with Diffuse Large B-Cell Lymphoma In the Rituximab Era

3949 The Effects of Co-Stimulatory Endodomains on the Fate of T Cells Expressing a Tumor Directed Chimeric Antigen Receptor (CAR) In Human Subjects with B Cell Malignancies

3950 Prospective Analysis of Hepatitis B Virus Reactivation In Patients with Diffuse Large B Cell Lymphoma After Rituximab Combination Chemotherapy

3951 Anti-MAG Neuropathy: a Single Center Retrospective Study In 61 Patients

3952 Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

3953 Low Dose Bexarotene and Ultraviolet A Photochemotherapy (PUVA) In a Prospective Phase II Clinical Study for Refractory and/or Resistant Cutaneous T Cell Lymphomas (CTCL)

3954 High-Dose Cyclophosphamide (Cy), Rituximab, and a Cancer Vaccine for Relapsed Classical Hodgkin's Lymphoma (cHL)

3955 Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study

3956 Rituximab Plus Chlorambucil Compared with Chlorambucil and Prednisone In Patients with Untreated Follicular Lymphoma

3957 A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma

3958 Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler’s Syndrome: a Series of 6 Cases

3959 ENGAGE- 501: Phase 2 Study Investigating the Role of Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory Hodgkin’s Lymphoma (HL), Interim Results

3960 Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

3961 Addition of Anti-Viral Therapy to Chemotherapy Improves Overall Survival In Acute and Lymphomatous Adult T-Cell Leukaemia/Lymphoma (ATLL)

3962 Phase II Trial of Lenalidomide - Dexamethasone - Rituximab In Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab

3963 PILLAR-1: Preliminary Results of a Phase II Study of mTOR Inhibitor Everolimus In Patients with Mantle Cell Lymphoma (MCL) Who Are Refractory or Intolerant to Bortezomib

3964 Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

3965 Weekly Infusion of Bortezomib In Combination with Rituximab In Relapsed/Refractory Indolent Non-Follicular and Mantle Cell Lymphoma Is Safe and Effective: Two-Years Analysis of Phase II Trial BRIL06 of Intergruppo Italiano Linfomi (IIL)

3966 Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Heavily Pre-Treated Low Grade Lymphoma and Diffuse Large Cell Lymphoma Patients

3967 Lenalidomide Overcomes FcγRIIIa-Mediated Resistance to Rituximab In Patients with Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL): A Correlative Analysis of a Phase 2 Study

3968 Hepatitis B Virus Reactivation In Surface Antigen-Negative Patients with B-Cell Non-Hodgkin's Lymphoma Treated with Rituximab

Non-Hodgkin Lymphoma - Biology, excluding Therapy: Poster III

4124 Self-Antigen Recognition by the B Cell Receptors of Follicular Lymphoma

4125 GATA-3 or T-Bet Expression In PTCL-U Identify High-Risk Patients with Poor Outcomes and Distinct Clinical Characteristics Suggesting Their Derivation From Specific Subsets of T Helper Cells

4126 The Immunohistochemical Profile and Other Prognostic Factors In Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Treated with R-CHOP

4127 Germline Variation in TNF and NF-Kappa B Pathways and Prognosis In Mantle Cell Lymphoma

4128 Peripheral Nerve Involvement (Neurolymphomatosis) as a Manifestation of Intravascular Large B-Cell Lymphoma

4129 The Prognosis of Limited Stage Peripheral T-Cell Lymphoma (PTCL): A Population-Based Analysis and Comparison to Diffuse Large B-Cell Lymphoma (DLBCL)

4130 The Autoantibody Response to ALK In Pediatric Anaplastic Large Cell Lymphoma: A Children’s Oncology Group Report

4131 Infliximab Drives Gamma-Delta T Cell Expansion In Crohn’s Disease – a Predictor of Lymphoma Risk?

4132 "Incidental Carcinomas" Detected by PET/CT Scans In the Patients with Malignant Lymphoma: A Single-Center Experience with 363 Patients 

4133 BLIMP1 Downregulates Expression of, LMO2 and HGAL, Proteins Highly Expressed In Germinal Center B Cells and Germinal Center-Derived Lymphomas

4134 Applicability of Different Immunohistochemistry Algorithms to Assess Gene Expression Profile In Patients with Diffuse Large B-Cell Lymphoma

4135 Analysis of Immunoglobulin Heavy Chain Variable Genes In Burkitt Lymphoma Uncovers An Antigen Role In the Pathogenesis of the Disease

4136 Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival

4137 Liver Infiltration In Splenic Marginal Zone Lymphoma: Prevalence and Prognostic Implication

4138 The Mystery of FDG-PET Avidity In Follicular Lymphoma. Does Microenvironment Play the Key Role?

4139 Immunoglobulin Heavy Chain (IGH) Gene Rearrangement In Waldenström Macroglobulinemia and Other Monoclonal IgM Disorders

4140 Profiles of Cytotoxic Molecules In Mature NK Cell Neoplasms

4141 IL-9 Contributes to Immunosupprssion Mediated by Regulatory T Cells and Mast Cells In B-Cell NHL

4142 High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Dose-Dense Chemoimmunotherapy and Systemic CNS Prophylaxis. Results From a Nordic Phase II Study

4143 Vitamins, Minerals, and Specialty Supplements and Risk of Hematological Malignancies In the VITamins and Lifestyle (VITAL) Cohort Study

4144 Leukemic T Cells Are Specifically Enriched In a Unique CD3dimCD7low Subpopulation of CD4+ T Cells In Acute-Type Adult T Cell Leukemia

4145 Anti-N-Terminal CD20 Monoclonal Antibody and L26 Dual Staining Identifies An Irreversible Resistant Mutant Genes

4146 Tryptophan Catabolism Is Associated with Clinical Outcome of Patients with Malignant Lymphoma

4147 Whole-Body Diffusion-Weighted Magnetic Resonance Imaging Is a New Sensitive Non-Invasive Method for Staging and Monitoring Chemotherapy Response of Malignant Lymphoma Including Indolent Lymphoma Compared with FDG-PET/CT

4148 Prognostic impact of circulating Epstein-Barr virus (EBV) DNA concentration and EBV serology in 125 extranodal NK/T cell lymphoma, nasal type (ENKL) patients

4149 Low Proliferation Index May Be Associated with Longer Time to First Therapy In Low Grade Follicular Lymphoma

4150 Primary Pancreatic Lymphoma

4151 Post Transplant Lymphoproliferative Disorders: Prognostic Features and Rituximab Impact In a 120 Case Single Institution Series

4152 Disease Characteristics and Patterns of Care In Elderly Patients (80+ years) with Follicular Lymphoma (FL) In the United States (US); Are Older Patients Treated Differently?  Report From the National LymphoCare Study (NLCS)

4153 The Role of PET Scan Imaging In Waldenstrom Macroglobulinemia

4154 Incidence and Risk Factors for Central Nervous System (CNS) Relapse In Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis with Competing Risk Regression (CRR) Model

4155 MicroRNA Signatures In B-Cell Lymphomas

4156 High Frequency of Marginal Zone Lymphomas Among Patients Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus - ANRS CO16 LYMPHOVIR Cohort Study

4157 Mirna EXPRESSION SIGNATURES as PROGNOSTIC Markers IN ADVANCED Classical HODGKIN LYMPHOMA

4158 Response Rate of 16% and High Incidence of Adverse Events In Placebo-Treated Patients with CD25 Assay-Positive Cutaneous T-Cell Lymphoma (CTCL): An Analysis of Patient Characteristics and Predictors of Response

4159 Associated Malignancies Among Patients and Kin with Waldenstrom’s Macroglobulinemia

4160 Dissecting the Genetic Basis of Marginal Zone Lymphoma Reveals a Predilection for NF-Kb Activation by Clonal MZL Located at Extranodal Sites

4161 Central Nervous System (CNS) Prophylaxis Does Not Decrease the Rates of CNS Relapse From Diffuse Large B-Cell Lymphoma In the Era of R-CHOP

4162 Plasmablastic Lymphoma: A Series of 16 Cases with the Largest Collection of 9 HIV-Negative Cases

4163 Increased Peripheral T Cell Responses to EBV-Infected Cells with Frequent Detection of EBV-DNA In Plasma and Viral mRNA In Peripheral B-Cells In Immunocompetent EBV-Positive Diffuse Large B-Cell Lymphoma Patients

4164 Gene Expression Profiling of Diffuse Large B-Cell Lymphomas Supervised by CD5 Expression

4165 Occurrence of T-Lymphocytes with Aberrant Immunophenotypes Suggestive of Mature T-Cell Neoplasms In Patients with Hairy Cell Leukemia

4166 Prevalence and Prognostic Factors of EBV-Positive DLBCL of the Elderly In Peru

4167 Smouldering Adult T-Cell Leukaemia/Lymphoma (ATLL) Is Not Associated with An Increased Risk of Aggressive ATLL In HTLV-1 Positive Patients

4168 Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes – Single Institution Experience

4169 The NF-κB Pathway Is Targeted by Multiple Genetic Lesions In Splenic Marginal Zone Lymphoma

Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Chemotherapy and PET in Non-Hodgkin Lymphoma

853 Rituximab and Reduced Dose CHOP (R-mini-CHOP) for Patients Over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – Groupe d’Etude Des Lymphomes De l’Adulte (GELA) Study LNH03-7B

854 FDG-PET Scan Guided Consolidative Radiation Therapy Optimizes Outcome In Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) with Residual Abnormalities on CT Scan Following R-CHOP

855 Result of FDG PET-CT Imaging After Immunochemotherapy Induction Is a Powerful and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: An Analysis From the PRIMA Study

856 Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

857 A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma

858 Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Novel approaches for T Cell and Mantle Cell Lymphoma

961 Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

962 Results of a Phase 1/2 Study for KW-0761, a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4), In CTCL Patients

963 Immune Characteristics Associated with Lymphomatoid Granulomatosis and Outcome Following Treatment with Interferon-Alpha

964 The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study

965 R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network

966 Salvage Treatment with Lenalidomide and Dexamethasone In Patients with Relapsed Refractory Mantle Cell Lymphoma: Clinical Results and Modifications of Angiogenic Biomarkers

Non-Hodgkin Lymphoma - Biology, excluding Therapy: New Biomarkers in Diffuse Large B-cell Lymphoma

991 Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients

992 The Genotype of MLH1 Is An Independent Predictor of Outcome In Diffuse Large B-Cell Lymphoma Treated with R-CHOP: a Training-Validation Study

993 Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study

994 VEGFA and VEGFR2 Genetic Polymorphisms and Survival In Patients with Diffuse Large B Cell Lymphoma

995 Characterization of the Copy-Number Changes In Primary CNS Lymphomas (PCNSL) by High-Resolution Array-Based Comparative Genomic Hybridization

996 Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma